E Fund Management Co., Ltd. Celldex Therapeutics, Inc. Transaction History

E Fund Management Co., Ltd.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$32.76 - $42.56 $58,574 - $76,097	-1,788 Reduced 19.77%	7,258 $268,000
Q1 2024 May 13, 2024	BUY	$35.22 - $51.88 $38,636 - $56,912	1,097 Added 13.8%	9,046 $379,000
Q4 2023 Feb 06, 2024	SELL	$22.61 - $40.65 $11,666 - $20,975	-516 Reduced 6.1%	7,949 $315,000
Q3 2023 Nov 13, 2023	SELL	$25.45 - $37.46 $65,839 - $96,909	-2,587 Reduced 23.41%	8,465 $233,000
Q2 2023 Aug 11, 2023	BUY	$30.29 - $38.28 $84,236 - $106,456	2,781 Added 33.62%	11,052 $375,000
Q1 2023 May 11, 2023	BUY	$34.78 - $47.43 $26,432 - $36,046	760 Added 10.12%	8,271 $298,000
Q4 2022 Feb 14, 2023	SELL	$27.78 - $45.38 $187,987 - $307,086	-6,767 Reduced 47.39%	7,511 $335,000
Q3 2022 Nov 14, 2022	BUY	$22.7 - $37.57 $1,770 - $2,930	78 Added 0.55%	14,278 $401,000
Q2 2022 Aug 15, 2022	BUY	$20.5 - $37.33 $130,421 - $237,493	6,362 Added 81.17%	14,200 $383,000
Q1 2022 May 12, 2022	BUY	$27.64 - $39.32 $76,396 - $108,680	2,764 Added 54.47%	7,838 $267,000
Q1 2021 May 12, 2021	BUY	$16.19 - $29.91 $82,148 - $151,763	5,074 New	5,074 $104,000

207

67.3M

1.69M

980K

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $1.23B
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.